Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

Military Medical Research

Review

Hazha Jamal Hidayat¹  Abbas Salihi²  Bashdar Mahmud Hussen³  Milladur Rahman⁴  Soudeh Ghafouri-Fard⁵  Goran Sedeeq Hama Faraj⁶  Fattma Abodi Ali⁷  Mohammed Fatih Rasul⁸  Wojciech Branicki⁹  Aria Baniahmad^1,10  Mohammad Taheri^1,11  Snur Rasool Abdullah^1,12  Mark C. Glassy^1,13 

[1]Department of Biology, College of Education, Salahaddin University-Erbil, 44001, Erbil, Kurdistan Region, Iraq

[2]Department of Biology, College of Science, Salahaddin University-Erbil, 44001, Erbil, Kurdistan Region, Iraq

[3]Center of Research and Strategic Studies, Lebanese French University, 44001, Erbil, Iraq

[4]Department of Biomedical Sciences, Cihan University-Erbil, 44001, Erbil, Kurdistan Region, Iraq

[5]Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, 44001, Erbil, Kurdistan Region, Iraq

[6]Department of Clinical Sciences, Malmö, Section for Surgery, Lund University, 22100, Malmö, Sweden

[7]Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, 374-37515, Tehran, Iran

[8]Department of Medical Laboratory Science, Komar University of Science and Technology, 46001, Sulaymaniyah, Iraq

[9]Department of Medical Microbiology, College of Health Sciences, Hawler Medical University, 44001, Erbil, Kurdistan Region, Iraq

[10]Department of Pharmaceutical Basic Science, Faculty of Pharmacy, Tishk International University, 44001, Erbil, Kurdistan Region, Iraq

[11]Faculty of Biology, Institute of Zoology and Biomedical Research, Jagiellonian University, 31-007, Kraków, Poland

[12]Institute of Human Genetics, Jena University Hospital, 07747, Jena, Germany

[13]Institute of Human Genetics, Jena University Hospital, 07747, Jena, Germany

[14]Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, 374-37515, Tehran, Iran

[15]Medical Laboratory Science, Lebanese French University, 44001, Erbil, Kurdistan Region, Iraq

[16]Translational Neuro-Oncology Laboratory, San Diego (UCSD) Moores Cancer Center, University of California, 94720, San Diego, CA, USA

关键词: CRISPR;    CRISPR/Cas9;    CRISPR/Cas12;    Gene editing;    miRNAs;    Cancer therapy;   

DOI  :  10.1186/s40779-023-00468-6

 received in 2023-01-27, accepted in 2023-07-03,  发布年份 2023

来源: Springer

【 摘 要 】

Clustered regulatory interspaced short palindromic repeats (CRISPR) has changed biomedical research and provided entirely new models to analyze every aspect of biomedical sciences during the last decade. In the study of cancer, the CRISPR/CRISPR-associated protein (Cas) system opens new avenues into issues that were once unknown in our knowledge of the noncoding genome, tumor heterogeneity, and precision medicines. CRISPR/Cas-based gene-editing technology now allows for the precise and permanent targeting of mutations and provides an opportunity to target small non-coding RNAs such as microRNAs (miRNAs). However, the development of effective and safe cancer gene editing therapy is highly dependent on proper design to be innocuous to normal cells and prevent introducing other abnormalities. This study aims to highlight the cutting-edge approaches in cancer-gene editing therapy based on the CRISPR/Cas technology to target miRNAs in cancer therapy. Furthermore, we highlight the potential challenges in CRISPR/Cas-mediated miRNA gene editing and offer advanced strategies to overcome them.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

13690_2023_1147_Article_IEq11.gif

Fig. 2

Fig. 3

Fig. 1

12862_2023_2148_Article_IEq5.gif

12862_2023_2133_Article_IEq61.gif